BVS

Bioventus Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05

Figures on this page computed 2026-11-08 12:01 UTC

Last close

10.61USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-03-05

  • 31.2xP/E

    Price / Earnings per Share (diluted)

    Source
    computed
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD
    • computed
    • 10-K for 2025, filed 2026-03-05

    The filing itself

  • n/aROIC

    We do not hold this figure for this company, so there is nothing to place.

    NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash

    Source
    computed
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-05
    • 10-K for 2025, filed 2026-03-05
    • 10-K for 2025, filed 2026-03-05
    • 10-Q for 2025, filed 2026-11-02
    • 10-K for 2025, filed 2026-03-05
    • 10-Q for 2025, filed 2026-11-02

    The filing itself

  • 4.0%Net margin

    Net Income / Revenue x 100

    Source
    computed
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-05
    • 10-K for 2025, filed 2026-03-05

    The filing itself

  • 12.7%FCF margin

    Free Cash Flow / Revenue x 100

    Source
    computed
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-05
    • 10-K for 2025, filed 2026-03-05

    The filing itself

  • 1.69Debt/equity

    Total Debt / Shareholders' Equity

    Source
    computed
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-05
    • 10-Q for 2025, filed 2026-11-02

    The filing itself

  • n/aDividend yield

    We do not hold this figure for this company, so there is nothing to place.

    Source
    computed
    Taken on
    2026-11-07
    Reported in
    USD
    • computed

What it sells, to whom

lens 8 of 9

What it sells

2
U.S. Segment502,097,000 USD88.4%
International Segment65,990,000 USD11.6%

Where it sells it

2
UNITED STATES502,097,000 USD88.4%
Non-US65,990,000 USD11.6%

Who it sells it to

1
Customer One11.4%

Each band is a share of itself. A segment and a place are two cuts of the same revenue, so they are never added together.

2 segments, 2 places and 1 named customers, each as the filer published it.

2 segments, 2 places and 1 named customers, each as the filer published it.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-05

  • U.S. Segment502,097,000
    Source
    filed
    Statement
    segments
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD

    The filing itself

  • International Segment65,990,000
    Source
    filed
    Statement
    segments
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD

    The filing itself

  • UNITED STATES502,097,000
    Source
    filed
    Statement
    revenue_mix
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD

    The filing itself

  • Non-US65,990,000
    Source
    filed
    Statement
    revenue_mix
    Fiscal year
    2025
    Accession
    0001665988-26-000011
    Reported in
    USD

    The filing itself

  • Customer One11.4%
    Source
    filed
    Statement
    concentration
    Fiscal year
    2025
    Accession
    0001665988-26-000011

    The filing itself

Filed figures cite the filing they come from; figures marked Market data are quotes as of the date shown. Not a recommendation and not advice.

Past figures are not a forecast. Anything we modelled is labelled as ours. You can lose money on any security.